Loading...
•
Mar 31
•/
BioNTech SE Q1 2025 Earnings Report
BioNTech reported a net loss and decreased revenue compared to Q1 2024, as expected due to seasonal demand for COVID-19 vaccines.
Key Takeaways
BioNTech's Q1 2025 results showed a net loss of €415.8 million on revenues of €182.8 million, primarily driven by reduced COVID-19 vaccine demand. The company continued advancing its oncology pipeline and maintained a strong cash position.
Revenue declined slightly to €182.8 million, mainly from COVID-19 vaccine collaboration.
Reported a net loss of €415.8 million and an EPS of -€1.73.
Strong financial position with €15.85 billion in cash and investments.
Focus remains on oncology programs, especially BNT327 combinations.
BioNTech SE
BioNTech SE
Forward Guidance
BioNTech expects total 2025 revenues between €1.7 billion and €2.2 billion, with revenue weighted toward year-end.
Positive Outlook
- Full-year revenue guidance reaffirmed.
- Strong financial position enables continued investment in oncology.
- Anticipated pandemic preparedness revenue from German government.
- Reimbursement of $535 million expected in 2025–2026 for settlements.
- Continued scaling for late-stage oncology commercial readiness.
Challenges Ahead
- No expectation of positive net income for FY2025.
- Vaccine demand concentrated in later months creates revenue timing risk.
- Potential inventory write-downs by partner Pfizer may impact revenue.
- Dependent on stable vaccination rates and public health policy.
- External legal risks and one-time effects excluded from guidance.